| Literature DB >> 26999421 |
Nikhil Patkar1, Kiran Ghodke1, Swapnali Joshi1, Shruti Chaudhary1, Russel Mascerhenas1, Sona Dusseja1, Shashikant Mahadik1, Sheetal Gaware1, Prashant Tembhare1, Sumeet Gujral1, Sharayu Kabre2, Pratibha Kadam-Amare2, Hasmukh Jain3, Uma Dangi3, Bhausaheb Bagal3, Navin Khattry3, Manju Sengar3, Brijesh Arora4, Gaurav Narula4, Shripad Banavali4, Hari Menon3, Papagudi Ganesan Subramanian1.
Abstract
We document the characteristics of BCR-ABL kinase domain mutations (KDM) in the largest study from India comprising of 385 patients and demonstrate that more than half (51.9%) of these patients have detectable abnormalities in the KD both in adult and in pediatric chronic myelogenous leukemia (CML). These comprise singly occurring missense mutations (25.5%), polyclonal/compound point mutations (4.9%), and insertions/deletions (29.6%). Missense mutations were most commonly seen in the imatinib-binding region followed by the P-loop. The commonest mutation in our dataset was T315I. Other common missense mutations were Y253H, M244V, and F317L. A high prevalence of BCR-ABL exon7 deletion (p.R362fs*) was also seen (25.5% of the entire cohort), whereas the 35bpintron-derived insertion/truncation mutation detected in 12 patients. In the pediatric age group, 58.8% of patients harbored missense mutations, polyclonal/compound mutations as well as insertions and deletions. We detected 11 novel mutations (seven missense mutations and four insertions/deletions).Entities:
Keywords: BCR-ABL Kinase domain mutations; CML India; imatinib resistance
Mesh:
Substances:
Year: 2016 PMID: 26999421 DOI: 10.3109/10428194.2016.1157868
Source DB: PubMed Journal: Leuk Lymphoma ISSN: 1026-8022